HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • HealthEconomics.Com On-demand Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
Home » News » ICER: Osteoporosis Anabolic Agents Priced Too High

ICER: Osteoporosis Anabolic Agents Priced Too High

In a Final Evidence Report on the comparative clinical effectiveness and value of teriparatide and abaloparatide, the Institute of Clinical and Economic Review (ICER) found the price of both agents was “too high.”

ICER logo for Berger reportTeriparatide and abaloparatide are anabolic agents used in osteoporosis treatments.

“Evidence suggests that, for the right patients, both teriparatide and abaloparatide provide benefit over no treatment, but the limited availability of data from head-to-head trials makes it difficult to ascertain whether the agents are more effective than existing alternatives, such as biophosphonates,” ICER Chief Medical Officer Dr. David Rind said in a press release.

Rind added the pricing of the agents is “too high in proportion to the benefit the provide, contributing to potential access barriers for patients.”

According to the release, an independent panel during the California Technology Assessment Forum also voted on evidence presented in the report.

The panel, among other things, found there was not enough evidence to suggest treatment with teriparatide and abaloparatide offers greater benefits over zoledronic acid.

Click here to read the Final Evidence Report on ICER’s website.

The full press release can be read here.



You might also be interested in:

  • Telehealth Could Advance Value-based Care in the US 12/15/2021
  • Navigating the CURES Act and Patient Access Final Rules: 7 Key… 12/01/2021
  • Real-World Evidence 2022: Rare Diseases and Innovative Therapies 02/15/2022
  • Call for Papers: Essen Health Conference 02/21/2022
  • Course Available: Introduction to Health Economics and… 02/09/2022
  • Study: Asian-American Health Impacted by Stereotypes and Poor Data 03/17/2022
  • Exploring Climate Change Through the Lens of Health Equity 05/25/2022

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

  • Manager, Statistical Analytics
  • Director / Senior Director, RWE
  • Research Analyst
  • Medical Writer
  • Associate Director/Director, Business Development
 
Syndicated Reports

Economic & Related Consulting Service Revenues World Report & Database

Healthcare Analytical Testing Services Market worth $9.8 billion by 2026 – Key Players are Eurofins Scientific, SGS S.A., Charles River Laboratories

Risk-Based Monitoring Software Market Worth $511 Million By 2025 – Growing Number Of Clinical Trials To Propel Market Growth

Real-World Evidence Solutions Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)

 
White Papers

The Augmented Rep: A practical field force guide for the Omnichannel era

Rare Disease’s Star Turn

The Next Generation of Information Management

Risk Mitigation for Pharma Manufacturer Programs

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • HealthEconomics.Com On-demand Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts